Trust these 00M-243 examcollection and go for actual test.

when you are searching on web for 00M-243 eBooks so there are huge number of 00M-243 eBooks on internet free of cost, but those are all outdated and you will risk your precious time and money. Go directly to killexams.com, download 100% free 00M-243 questions PDF sample. Evaluate and register for full version. Practice 00M-243 dumps and pass the exam.

Exam Code: 00M-243 Practice test 2022 by Killexams.com team
IBM Optimization Supply Chain Mgmt Sales Mastery Test v1
IBM Optimization health
Killexams : IBM Optimization health - BingNews https://killexams.com/pass4sure/exam-detail/00M-243 Search results Killexams : IBM Optimization health - BingNews https://killexams.com/pass4sure/exam-detail/00M-243 https://killexams.com/exam_list/IBM Killexams : BigBear.ai Names Former IBM Executive Mandy Long as Chief Executive Officer

Dr. Reggie Brothers Steps Down as CEO and Board Member, Remains Advisor to Company

BigBear.ai BBAI, a leader in AI-powered analytics and cyber engineering solutions, today announced that the Board of Directors has appointed former IBM executive Amanda "Mandy" Long as Chief Executive Officer and member of the Board of Directors, effective October 12, 2022. Dr. Reggie Brothers will step down as Chief Executive Officer and from the Board of Directors, transitioning to serve as a Company advisor and Operating Partner at AE Industrial Partners.

Long joins BigBear.ai with 15 years of experience in software and hardware across multiple industries, most recently as an executive at IBM, where she successfully led organizations to launch multiple first-of-their-kind products and made significant contributions to the rapid growth of the IBM Watson artificial intelligence (AI) franchise. During her tenure at IBM, Long had full P&L responsibility for several large and complex global businesses, developing strategies to drive customer adoption of AI and other automation solutions. Long also played a key leadership role in IBM's organizational transformation, leading the integration and optimization of new business lines for acquired assets, and introducing scalable operational processes, diverse talent curation and retention strategies, and pipeline management strategies.

"Mandy has an impressive record of building global technology portfolios and driving revenue growth and adoption of AI products. She has extensive M&A experience, deep software product experience in regulated and unregulated industries, and has implemented innovative and collaborative workplace environments at scale. With Mandy at the helm, we expect to accelerate BigBear.ai's ability to bring AI-based products to both Commercial and Federal markets as the Company transitions from a premier services and solutions provider to a technology-led, multi-market leader in AI," said Peter Cannito, Chairman of the BigBear.ai Board of Directors.

Cannito continued, "Reggie has been instrumental in creating the BigBear.ai vision of putting the power of AI into the hands of decision makers to Excellerate visibility, predictability, and outcomes for critical missions. We are grateful for his leadership in establishing BigBear.ai as a public company, building an experienced and resilient team, and bringing the Company to this point in its lifecycle."

"I am honored to be named CEO of BigBear.ai, a dynamic company whose technology and expertise is trusted to solve so many critical challenges for our customers – from protecting our nation to helping hospitals deliver the right care at the right time to children who need it most," said Long. "The opportunity to support the Company in productizing our unique technology assets, scaling into a market leader, and capitalizing on the rapidly growing demand for AI /ML solutions in every sector is a dream come true."

Executive Bio

Mandy Long previously served as Vice President, IBM IT Automation and Vice President, IBM Integration & Application Platform. Prior to that, she served as General Manager, IBM Watson Health Provider Analytics, as well as Chief Product and Strategy Officer, Artificial Intelligence for IBM Watson. She also previously held Vice President of Product Management positions at Modernizing Medicine and Experian Health. Mandy has received multiple awards and recognition for her accomplishments in the fields of Healthcare IT, including as one of the Most Powerful Women in Healthcare IT from Health Data Management in 2017. She earned a B.A. in Economics from Connecticut College.

About BigBear.ai

BigBear.ai delivers AI-powered analytics and cyber engineering solutions to support mission-critical operations and decision-making in complex, real-world environments. BigBear.ai's customers, which include the US Intelligence Community and Department of Defense, as well as customers in manufacturing, healthcare, commercial space, and other sectors, rely on BigBear.ai's solutions to see and shape their world through reliable, predictive insights and goal-oriented advice. Headquartered in Columbia, Maryland, BigBear.ai is a global, public company traded on the NYSE under the symbol BBAI. For more information, please visit: https://bigbear.ai/ and follow BigBear.ai on Twitter: @BigBearai.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tue, 11 Oct 2022 08:30:00 -0500 text/html https://www.benzinga.com/pressreleases/22/10/b29226553/bigbear-ai-names-former-ibm-executive-mandy-long-as-chief-executive-officer
Killexams : Aktana Welcomes New Medical Affairs Lead from IBM Watson Health (Now Merative)

Deepak Patil brings deep data science experience in life sciences to drive Aktana's medical affairs team in response to growing need for improved healthcare professional engagement

Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy. Patil comes to Aktana after leadership roles at IBM Watson Health, IQVIA, and Sun Pharma Industries (Mumbai, India), where he managed medical affairs in conjunction with six key product launches and developed lasting relationships with key opinion leaders in targeted therapeutic areas. At Aktana, Patil will lead the company's medical affairs program, initially helping to build modern, data-driven solutions for medical science liaisons (MSLs), but over time, also expand to other areas within medical affairs.

Medical Affairs is the "third strategic pillar of the pharmaceutical organization alongside R&D and commercial, as science and data merge," according to a McKinsey report. Business models are starting to evolve both around and beyond the "product" to encompass the wider therapeutic context, while organizations seek to explain and contextualize the ever more complex medical science to a diverse range of stakeholders (physicians, patients, payers). In outreach efforts, MSLs and commercial teams can unintentionally overlap, causing major compliance issues and frustrating doctors. Aktana's intelligence solutions will not only help medical affairs Excellerate key opinion leader relationships but also better orchestrate outreach to the physician community in compliance with regional engagement regulations.

"Deepak brings a unique blend of medical experience – he received his medical degree in India – plus data science and operational expertise from IQVIA and IBM," said Clay Hausmann, chief revenue officer at Aktana. "As we prioritize new, AI-driven solutions for medical affairs teams, Deepak will help expertly shape our new offerings while building a powerhouse team focused on this increasingly important area of life sciences."

Aktana has also announced a strategic partnership with Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs. Envision and Aktana will combine their offerings to help MSLs address HCP demands for personalized scientific content and coordinated omnichannel engagement.

"Aktana is committed to enabling the medical affairs organization in a new era, and I'm excited to serve in a leadership role as part of this endeavor," said Deepak Patil. "The real-world data is there. With the right technology, we have the power to Excellerate the generation and dissemination of scientific insights to physicians, leading to better treatment decisions and outcomes for their patients."

With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana's Contextual Intelligence 360 platform is powered by the company's next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI.

About Aktana

Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana's AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Mon, 26 Sep 2022 23:49:00 -0500 text/html https://www.benzinga.com/pressreleases/22/09/b29027122/aktana-welcomes-new-medical-affairs-lead-from-ibm-watson-health-now-merative
Killexams : IBM: A High-Yielding Income Generation Idea Worth A Look
Day 1 - Mobile World Congress 2022

David Ramos

By The Valuentum Team

International Business Machines Corporation (NYSE:IBM) has become a fundamentally different business in the past few years, one focused on providing hybrid cloud computing offerings. The company is a stellar free cash flow generator which enables IBM to reward investors via generous dividend increases, with shares of IBM yielding ~5.1% as of this writing. Substantial near-term headwinds remain, largely due to the various exogenous shocks seen of late (such as major inflationary pressures, rising interest rates, supply chain hurdles, and raging geopolitical tensions), though IBM is still worth considering as a high-yielding income generation idea.

IBM's Key Investment Considerations

Investment Considerations

Image Source: Valuentum

IBM solves business problems via integrated hardware/software solutions that leverage IT and its knowledge of business processes. Its solutions help reduce a client's costs or enable new capabilities that generate revenue. The company was founded in 1924 and is headquartered in New York.

Back in 2019, IBM bought Red Hat (a top provider of open source cloud software) through a ~$34 billion deal which made IBM a contending hybrid cloud provider. IBM is looking to seize what it describes as a ~$1 trillion hybrid cloud opportunity, and accurate growth in this area has been encouraging. IBM's revamped management team is working hard to turn things around after the company made various blunders during the 2010s decade. Its current Chairman and CEO, Arvind Krishna, has done a solid job righting the ship at IBM since taking on the top role in 2020.

In November 2021, IBM spun off its legacy business tax-free to shareholders as a new publicly traded entity, Kyndryl Holdings, Inc. (KD). Initially, IBM retained a 19.9% stake in Kyndryl though the firm intends to exit that position within 12 months of the spinoff.

Earnings Update

On July 18, IBM reported earnings for the second quarter of 2022 that beat both consensus top- and bottom-line estimates. Its GAAP revenues rose by 9% year-over-year to hit $15.5 billion with strong growth at its Red Hat, various consulting services, and hybrid infrastructure offerings being key here. When removing foreign currency headwinds arising from the strong US dollar seen of late from the picture, IBM's non-GAAP constant currency revenues were up 16% year-over-year last quarter. IBM's portfolio optimization efforts are having a very powerful impact on its financial performance.

The firm's GAAP gross margin fell by ~185 basis points year-over-year last quarter, falling down to 55.4%. However, economies of scale helped drive its GAAP income from continuing operations up by 81% year-over-year in the second quarter, rising to $1.5 billion. There is some noise here due to the separation of IBM's legacy businesses (via the spinoff of Kyndryl) from its core operations. Keeping that noise in mind, IBM's underlying operations have performed quite well of late.

During its second quarter earnings call, IBM's management team noted the firm now forecasted that its full-year free cash flows would come in near $10.0 billion in 2022, at the low end of its previous forecast. IBM generated $3.6 billion in free cash flow (defined as net operating cash flow less 'payments for property, plant, and equipment' and 'investment in software') while spending $3.0 billion covering its dividend obligations during the first half of 2022. Its modest share repurchases during this period were related to tax withholding purposes as the new IBM is focused on retaining cash to invest in the business. We appreciate that IBM's dividend obligations remain well-covered by its traditional free cash flows.

The company exited June 2022 with a net debt load of $42.8 billion (inclusive of short-term debt, exclusive of restricted cash). One of the biggest risks to IBM's dividend is its large net debt load. IBM had $7.6 billion in cash, cash equivalents, and current marketable securities on hand at the end of June 2022 which provides the company with ample liquidity to meet its near-term funding needs.

IBM continues to expect that its constant currency revenues will grow decently this year (in the mid-single digit range), though sustained foreign currency headwinds are expected to offset strong demand for its offerings, to a degree. Over the long haul, we forecast that under its new management team, IBM will return to stable revenue growth which in turn should see the company's free cash flows swell higher. That would allow IBM to boost its dividend in a sustainable manner going forward, though we caution that its net debt load could limit the size of any future payout increases.

Dividend Analysis

Table of IBM's Dividend Cushion ratio as derived by Valuentum.

IBM's forward-looking dividend coverage is weighed down negatively by its large net debt load. (Valuentum)

The Dividend Cushion Ratio Deconstruction, shown in the image up above, reveals the numerator and denominator of the Dividend Cushion ratio. At the core, the larger the numerator, or the healthier a company's balance sheet and future free cash flow generation, relative to the denominator, or a company's cash dividend obligations, the more durable the dividend.

The Dividend Cushion Ratio Deconstruction image puts sources of free cash in the context of financial obligations next to expected cash dividend payments over the next 5 years on a side-by-side comparison. Because the Dividend Cushion ratio and many of its components are forward-looking, our dividend evaluation may change upon subsequent updates as future forecasts are altered to reflect new information.

In the context of the Dividend Cushion ratio, IBM's numerator is smaller than its denominator, which suggests weak forward-looking dividend coverage. However, given IBM's strong and stable cash flow profile, we view its forward-looking dividend coverage favorably when considering IBM's ability to tap capital markets into account. Should IBM stumble for any reason, its ability to make good on its payout may be in danger.

IBM's Economic Profit Analysis

The best measure of a firm's ability to create value for shareholders is expressed by comparing its return on invested capital ['ROIC'] with its weighted average cost of capital ['WACC']. The gap or difference between ROIC and WACC is called the firm's economic profit spread. IBM's 3-year historical return on invested capital (without goodwill) is 41.6%, which is above the estimate of its cost of capital of 9.2%.

In the chart down below, we show the probable path of ROIC in the years ahead based on the estimated volatility of key drivers behind the measure. The solid grey line reflects the most likely outcome, in our opinion, and represents the scenario that results in our fair value estimate. Assuming IBM's accurate portfolio optimization efforts go as planned, the firm's ability to generate shareholder value (which historically has been impressive) should continue to improve.

Adjusted Return on Invested Capital

Image Source: Valuentum

IBM's Cash Flow Valuation Analysis

Cash Flow Generation

Image Source: Valuentum

Our discounted cash flow process values each firm on the basis of the present value of all future free cash flows, net of balance sheet considerations. We think IBM is worth $136 per share with a fair value range of $101-$171 per share. Shares of IBM are trading moderately below our fair value estimate as of this writing.

The near-term operating forecasts used in our enterprise cash flow model, including revenue and earnings, do not differ much from consensus estimates or management guidance. Our model reflects a compound annual revenue growth rate of 3.4% during the next five years, a pace that is higher than the firm's 3-year historical compound annual growth rate of -10.3%.

Our model reflects a 5-year projected average operating margin of 17.6%, which is above IBM's trailing 3-year average. Beyond Year 5, we assume free cash flow will grow at an annual rate of 2% for the next 15 years and 3% in perpetuity. For IBM, we use a 9.2% weighted average cost of capital to discount future free cash flows.

Valuation Assumptions

Image Source: Valuentum

Valuation Breakdown

Image Source: Valuentum

IBM's Margin of Safety Analysis

Range of Potential Outcomes

Image Source: Valuentum

Although we estimate IBM's fair value at about $136 per share, every company has a range of probable fair values that's created by the uncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future were known with certainty, we wouldn't see much volatility in the markets as stocks would trade precisely at their known fair values.

In the graphic up above, we show this probable range of fair values for IBM. We think the firm is attractive below $101 per share (the green line), but quite expensive above $171 per share (the red line). The prices that fall along the yellow line, which includes our fair value estimate, represent a reasonable valuation for the firm, in our opinion.

Concluding Thoughts

The steady decline in IBM's legacy business since 2010 represents a major reason why the firm spun off Kyndryl in November 2021. Going forward, IBM will need to prove that as a leaner and more focused enterprise, it can maintain solid revenue and operating income growth over the long haul. We think that will be the case, though substantial near-term headwinds remain. Investors looking for an income generation idea backed up by a strong cash flow profile should take a closer look at IBM.

Tue, 20 Sep 2022 20:10:00 -0500 en text/html https://seekingalpha.com/article/4542216-ibm-stock-high-yielding-income-generation-idea-worth-look
Killexams : Global Health Cloud Market Size and Outlook 2022 by Classification, Market Trend Analysis, Threats and Forecast till 2028 Research Report

The MarketWatch News Department was not involved in the creation of this content.

Oct 04, 2022 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry."

Global “Health Cloud Market” report provides information on topmost companies in the Health Cloud market are commonly focused on innovative opportunities associated to the invention and supply of Health Cloud. These strategies will let the key players to cover their business limits and increase their position in the market. The report appraise various segments includes industry types, applications and regions. Furthermore, the report provides comprehensive analysis on sales revenue, key growth patterns, key suppliers details, demand-supply scenario, and developing strategies worldwide.

Get a sample PDF of the Report - https://www.absolutereports.com/enquiry/request-sample/21473328

Market Analysis and Insights: Global Health Cloud Market

The Health Cloud market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, accurate developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Due to COVID-19 pandemic, the global Health Cloud market size is estimated to be worth USD million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Food and Beverage accounting for % of the Health Cloud global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Fully Automatic Carton Sealers segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Health Cloud include Lantech, 3M, Intertape Polymer Group, BestPack, and OPITZ Packaging Systems, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Health Cloud market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

The major players covered in the Health Cloud market report are:

● Microsoft Corporation (US) ● IBM Corporation (US) ● Oracle Corporation (US) ● Salesforce.com Inc. (US) ● General Electric Company (US) ● Cisco Systems Inc. (US) ● Siemens AG (Germany) ● Cleardata Networks Inc. (Us)

Get a sample Copy of the Health Cloud Market Report 2022

Market segment by Type, covers

● Clinical Data Management
● Analytics and Assessments
● Data Storage
● Care Management
● Others

Market segment by Application can be divided into

● Private
● Public
● Others

To Understand How Covid-19 Impact Is Covered in This Report - https://www.absolutereports.com/enquiry/request-covid19/21473328

Market segment by region, regional analysis covers

● North America (United States, Canada and Mexico) ● Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe) ● Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia) ● South America (Brazil, Argentina, Colombia, and Rest of South America) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East and Africa)

The content of the study subjects, includes a total of 15 chapters:

● Chapter 1, to describe Health Cloud product scope, market overview, market opportunities, market driving force and market risks. ● Chapter 2, to profile the top manufacturers of Health Cloud, with price, sales, revenue and global market share of Health Cloud from 2019 to 2022. ● Chapter 3, the Health Cloud competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. ● Chapter 4, the Health Cloud breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028. ● Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028. ● Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Health Cloud market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028. ● Chapter 12, the key raw materials and key suppliers, and industry chain of Health Cloud. ● Chapter 13, 14, and 15, to describe Health Cloud sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Inquire or Share Your Questions If Any before the Purchasing This Report -https://www.absolutereports.com/enquiry/pre-order-enquiry/21473328

Questions answered in the Health Cloud market research report:

● What is the Health Cloud market size? ● What are the market driving factors behind the Health Cloud market? ● What are the market trends and forecast for the global Health Cloud market? ● What are the trends and forecasts based on market research and analysis of Health Cloud market segmentation by type, application, geography? ● Which are the major global Health Cloud companies? ● What is the CAGR and Revenue expected in future?

Detailed TOC of Global Health Cloud Market 2022 by Manufacturers, Regions, Typeand Application, Forecast to 2028

1 Health Cloud Market Overview

1.1 Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Revenue by Type: 2017 Versus 2021 Versus 2028

1.3 Market Analysis by Application

1.4 Global Market Size and Forecast

1.4.1 Global Sales in Value (2017 and 2021 and 2028)

1.4.2 Global Sales in Volume (2017-2028)

1.4.3 Global Price (2017-2028)

1.5 Global Production Capacity Analysis

1.5.1 Global Total Production Capacity (2017-2028)

1.5.2 Global Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Health Cloud Market Drivers

1.6.2 Health Cloud Market Restraints

1.6.3 Health Cloud Trends Analysis

2 Manufacturers Profiles

2.1 Manufacture 1

2.1.1 Manufacture 1 Details

2.1.2 Manufacture 1 Major Business

2.1.3 Manufacture 1 Health Cloud Product and Services

2.1.4 Manufacture 1 Health Cloud Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Manufacture 2

2.2.1 Manufacture 2 Details

2.2.2 Manufacture 2 Major Business

2.2.3 Manufacture 2 Health Cloud Product and Services

2.2.4 Manufacture 2 Health Cloud Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 Manufacture 3

2.3.1 Manufacture 3 Details

2.3.2 Manufacture 3 Major Business

2.3.3 Manufacture 3 Health Cloud Product and Services

2.3.4 Manufacture 3 Health Cloud Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Purchase this Report (Price 3480 USD for a Single-User License) -https://www.absolutereports.com/purchase/21473328

3 Health Cloud Breakdown Data by Manufacturer

3.1 Global Health Cloud Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Health Cloud Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Health Cloud

3.4 Market Concentration Rate

3.4.1 Top 3 Health Cloud Manufacturer Market Share in 2021

3.4.2 Top 6 Health Cloud Manufacturer Market Share in 2021

3.5 Global Health Cloud Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Health Cloud Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers and Acquisitions

4 Health Cloud Market Analysis by Region

4.1 Global Market Size by Region

4.1.1 Global Sales in Volume by Region (2017-2028)

4.1.2 Global Revenue by Region (2017-2028)

4.2 North America Health Cloud Revenue (2017-2028)

4.3 Europe Health Cloud Revenue (2017-2028)

4.4 Asia-Pacific Revenue (2017-2028)

4.5 South America Revenue (2017-2028)

4.6 Middle East and Africa Revenue (2017-2028)

5 Health Cloud Market Segment by Type

5.1 Global Sales in Volume by Type (2017-2028)

5.2 Global Revenue by Type (2017-2028)

5.3 Global Price by Type (2017-2028)

6 Health Cloud Market Segment by Application

6.1 Global Sales in Volume by Application (2017-2028)

6.2 Global Revenue by Application (2017-2028)

6.3 Global Price by Application (2017-2028)

7 North America by Country, by Type, and by Application

7.1 North America Health Cloud Sales by Type (2017-2028)

7.2 North America Health Cloud Sales by Application (2017-2028)

7.3 North America Health Cloud Market Size by Country

7.3.1 North America Health Cloud Sales in Volume by Country (2017-2028)

7.3.2 North America Health Cloud Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Application

8.1 Europe Health Cloud Sales by Type (2017-2028)

8.2 Europe Health Cloud Sales by Application (2017-2028)

8.3 Europe Health Cloud Market Size by Country

8.3.1 Europe Health Cloud Sales in Volume by Country (2017-2028)

8.3.2 Europe Health Cloud Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Application

9.1 Asia-Pacific Health Cloud Sales by Type (2017-2028)

9.2 Asia-Pacific Health Cloud Sales by Application (2017-2028)

9.3 Asia-Pacific Health Cloud Market Size by Region

9.3.1 Asia-Pacific Health Cloud Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Health Cloud Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

Get a sample Copy of the Health Cloud Market Report 2022

10 South America by Region, by Type, and by Application

10.1 South America Health Cloud Sales by Type (2017-2028)

10.2 South America Health Cloud Sales by Application (2017-2028)

10.3 South America Health Cloud Market Size by Country

10.3.1 South America Health Cloud Sales in Volume by Country (2017-2028)

10.3.2 South America Health Cloud Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East and Africa by Country, by Type, and by Application

11.1 Middle East and Africa Health Cloud Sales by Type (2017-2028)

11.2 Middle East and Africa Health Cloud Sales by Application (2017-2028)

11.3 Middle East and Africa Health Cloud Market Size by Country

11.3.1 Middle East and Africa Health Cloud Sales in Volume by Country (2017-2028)

11.3.2 Middle East and Africa Health Cloud Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Health Cloud and Key Manufacturers

12.2 Manufacturing Costs Percentage of Health Cloud

12.3 Health Cloud Production Process

12.4 Health Cloud Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Health Cloud Typical Distributors

13.3 Health Cloud Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

For Detailed TOC - https://www.absolutereports.com/TOC/21473328#TOC

Contact Us:

Absolute Reports

Phone : US +1 424 253 0807

UK +44 203 239 8187

Email : sales@absolutereports.com

Web : https://www.absolutereports.com

Our Other Reports:

Global Electroencephalographs Market Size 2022 Study Report by Impact of COVID-19, Development Trends, Threats, Opportunities and Forecast till 2026

Global Digital Surgery Market Size 2022 Study Report by Market Performance Analysis, Development Trends, Threats, Opportunities and Forecast till 2026

Global Multi Touch Digital Device Market Size and Outlook 2022 by End users Market Analysis, Production Cost Structure Benchmarks and Forecast till 2028 Research Report

Global Pets External Medicine Market Size and Outlook 2022 by Upstream, Cost Analysis, New Technologies, Market Dynamics and Forecast till 2028 Research Report

Smart Home System Market Size 2022 Global Industry Investigation by Share, Trends, Growth Factors, Developments, Product Innovation and Forecast till 2028

Radius Milling Cutters Market Size 2022 Research Report by Business Growth, Emerging Demand, Regional Opportunities, Revenue, SWOT Analysis and Forecast till 2028

Global Spiral Chute Market Size 2022 Study Report by Impact of COVID-19, Development Trends, Threats, Opportunities and Forecast till 2026

Global Automotive Lightweight Materials Market Size 2022 Study Report by PEST analysis, Production Types, Development Trends, Threats, Opportunities and Forecast till 2026

Global Aluminium Chlorohydrate (ACH) Market Size and Outlook 2022 by Revenue Growth, Profitability, Industry Trends, Market Share Estimates and Forecast till 2028 Research Report

Citric Acid Monohydrate Market Size 2022 Research Report by Trends, Market Dynamics, Latest Developments, Driving Factors and Forecast till 2028

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Global Health Cloud Market Size and Outlook 2022 by Classification, Market Trend Analysis, Threats and Forecast till 2028 Research Report

COMTEX_415865184/2598/2022-10-04T01:52:35

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.

Mon, 03 Oct 2022 17:52:00 -0500 en-US text/html https://www.marketwatch.com/press-release/global-health-cloud-market-size-and-outlook-2022-by-classification-market-trend-analysis-threats-and-forecast-till-2028-research-report-2022-10-04
Killexams : ConvergeOne Collaborates with Redox to Deliver an Improved Patient Experience for Healthcare Organizations

BLOOMINGTON, Minn., Oct. 12, 2022 /PRNewswire/ -- ConvergeOne, the preeminent services-led provider of cloud, collaboration and digital modernization solutions, and Redox, the market-leading healthcare interoperability solution, today announced a collaborative partnership.

ConvergeOne Logo. (PRNewsFoto/NACR) (PRNewsFoto/)

Through this relationship, ConvergeOne's C1Conversations platform — a cloud-based solution that accelerates digital transformations and protects investments in contact center infrastructure — is now capable of integrating with 90+ leading Electronic Health Records or Electronic Medical Records (EHR/EMR) providers. With the integration of Redox, C1Conversations makes it possible for healthcare organizations to deliver an improved patient experience in weeks rather than months.

C1Conversations and Redox will provide healthcare clients the ability to preserve their existing infrastructure investments and upgrade best-in-breed solutions whether on-prem, hybrid cloud, or multi-cloud, while satisfying the needs of the CTO, CIO and Chief Patient Experience Officer. With Redox integration, C1Conversations' Intelligent Virtual Agent (IVA) will deliver market-leading patient experience automation and optimization in multiple languages, with record voice and digital containment rates.

The combined cloud-based service, to be introduced to clients as C1Conversations' EHR Data Access, is uniquely able to deliver a modern and improved patient experience in a streamlined "time to value" horizon.

"As a significant percentage of healthcare providers continue to operate with legacy and on-premises contact center infrastructures, the integration of Redox into C1Conversations creates an ideal proposition to our existing healthcare customers and the market segment in general," said Phil Yeich, Senior Director of Product Management, ConvergeOne. "By combining Redox's powerful healthcare ecosystem and exchange capabilities with ConvergeOne's IP, award-winning managed services and world-class Net Promoter Score, we are poised to provide existing contact center investments with a painless modernization path."

"As the quintessential thought leader in customer and agent experience (C/AX), ConvergeOne understands the dynamics of the contact center space and its intricate impact on healthcare organizations. The combination of the C1Conversations and Redox platforms allows us to meet the evolving technology needs and high service-level standards of healthcare clients," said Mark Langanki, CTO, ConvergeOne. "This strategic collaboration will allow us to help our healthcare clients who are interested in making their contact center infrastructure cloud-relevant without replacing it."

About ConvergeOne

ConvergeOne is a proven, services-led cloud and applications solution provider that utilizes its intellectual property and unique methodologies to create value for customers and develop progressive solutions that connect people with purpose. Over 14,000 enterprise and mid-market customers trust ConvergeOne to achieve their business outcomes with cloud, collaboration, enterprise networking, data center and cyber security solutions. Our investments in cloud infrastructure and professional and managed services provide transformational opportunities for customers to achieve financial and operational benefits with leading technologies. Our 2021 NPS of 80, placing us in the World Class category for the fourth consecutive year, is a testament to our ability to provide customers with the highest level of customer satisfaction, responsiveness and expertise. ConvergeOne has partnerships with more than 300 global industry leaders, including Dell Technologies, AWS, Avaya, Cisco, IBM, Genesys and Microsoft to customize specific business outcomes. We deliver solutions with a total lifecycle approach, including strategy, design and implementation with professional, managed and support services. ConvergeOne holds more than 5,600 technical certifications across hundreds of engineers throughout North America, including three Customer Success Centers. More information is available at convergeone.com.

About C1Conversations

Part of ConvergeOne's Intellectual Property portfolio, C1Conversations is an Integration Platform as a Service (IPaaS) that orchestrates the integration of next-gen applications, cloud solutions, internal databases, and systems (CRM, ITSM, ERP) for on-prem, cloud, or next-gen Contact Center Infrastructure. C1Conversations' Microservices Architecture accelerates the Digital Transformation of existing Contact Center Infrastructure – in weeks, not months – leveraging current investments & accrued knowledge without the need to "Rip & Replace." C1Conversations orchestrates the interaction of all these sources and their data to create insights while eliminating the complexity of tactical off-the-shelf solution integrations. C1Conversations de-risks future technology decisions and delivers CX innovation while creating a clear Competitive Advantage and Brand Loyalty. Learn more at c1conversations.com.

About Redox

Payers, providers, digital health companies, and other healthcare entities use Redox to produce differentiated experiences for patients and clinicians. Connecting to more than 30,000 healthcare organizations, Redox provides a composable software experience across the healthcare ecosystem. With our single API, product teams are empowered to build whatever they can imagine. Redox accelerates innovations that make healthcare data more useful than ever before. Learn more at redoxengine.com.

ConvergeOne Media Contact:
Craig Chumley
EVP, Corporate Marketing
678.262.2242
cchumley@convergeone.com

Redox Media Contact:
Miona Short
miona@redoxengine.com

Cision

View original content to get multimedia:https://www.prnewswire.com/news-releases/convergeone-collaborates-with-redox-to-deliver-an-improved-patient-experience-for-healthcare-organizations-301646942.html

SOURCE ConvergeOne

Wed, 12 Oct 2022 00:00:00 -0500 en-US text/html https://www.yahoo.com/lifestyle/convergeone-collaborates-redox-deliver-improved-120000246.html
Killexams : IBM’s Cloud Acquisition Charge Continues With Dialexa

Cloud News

Mark Haranas

IBM continues to spend millions to buy hybrid cloud companies, as the company makes its sixth acquisition in 2022 with Dialexa.

 ARTICLE TITLE HERE

IBM continues to spend millions on buying hybrid cloud companies with the unveiling of its acquisition of engineering consulting specialist Dialexa to boost its cloud charge.

Since IBM CEO Arvind Krishna took the reins in April 2020, IBM has acquired more than 25 companies, including many hybrid cloud businesses.

In February alone, IBM acquired cloud consultant services standout Sentaca, as well as Microsoft Azure consultancy all-star Neudesic—with the two purchases squarely aimed at boosting IBM’s hybrid and multi-cloud services capabilities.

[Related: UK To Probe Amazon, Google, Microsoft’s Cloud Dominance]

Looking at the Armonk, N.Y.-based company’s purchase of Dialexa, IBM will gain 300 skilled product managers, designers, full-stack engineers and data scientists. Dialexa will become part of IBM’s Consulting business unit, which spearheads the company’s digital product engineering services in the Americas.

“Dialexa’s product engineering expertise, combined with IBM’s hybrid cloud and business transformation offerings, will help our clients turn concepts into differentiated product portfolios that accelerate growth,” said John Granger, senior vice president of IBM Consulting, in a statement.

Krishna: Hybrid Cloud A ‘Competitive Advantage’

Dialexa marks IBM’s sixth purchase in 2022 with the goal of boosting its hybrid cloud and artificial intelligence abilities.

Along with buying Dialexa, Sentaca and Neudesic, IBM has also acquired Randori, an attack surface management cybersecurity specialist that helps protect hybrid cloud environments.

Earlier this year, IBM’s CEO said hybrid cloud and artificial intelligence are top of mind for his company in terms of investment and the future.

“We are integrating technology and expertise—from IBM, our partners and even our competitors—to meet the urgent needs of our clients, who see hybrid cloud and AI as crucial sources of competitive advantage,” Krishna said in March. “And we are ready to be the catalyst of progress for our clients as they pursue the digital transformation of the world’s mission-critical businesses.”

In 2021, IBM’s hybrid cloud revenue jumped 19 percent compared with 2020, comprising 35 percent of its total revenue.

IBM’s Acquisition Of Dialexa

Based in Dallas and Chicago, Dialexa delivers a suite of digital product engineering services to help customers create transformative products to drive business outcomes.

Dialexa’s 300-strong engineers and skilled IT experts advise and create custom digital products for customers, which include Deere & Company, Pizza Hut U.S. and Toyota Motor North America. Financial terms of the Dialexa deal were not disclosed.

IBM said Dialexa provides deep experience delivering end-to-end digital product engineering services consisting of strategy, design, build, launch and optimization services across cloud platforms including Amazon Web Services and Microsoft Azure.

“Digital product engineering represents the tip of the spear for competitive advantage,” said Dialexa CEO Scott Harper in a statement. “IBM and Dialexa’s shared vision for delivering industry-defining digital products could be a game-changer.”

Mark Haranas

Mark Haranas is an assistant news editor and longtime journalist now covering cloud, multicloud, software, SaaS and channel partners at CRN. He speaks with world-renown CEOs and IT experts as well as covering breaking news and live events while also managing several CRN reporters. He can be reached at mharanas@thechannelcompany.com.

Fri, 23 Sep 2022 09:04:00 -0500 en text/html https://www.crn.com/news/cloud/ibm-s-cloud-acquisition-charge-continues-with-dialexa
Killexams : IBM Acquires Dialexa

IBM (NYSE:IBM) acquired Dialexa, a Dallas TX and Chicago, IL-based digital product engineering services firm.

The amount of the deal was not disclosed. The transaction is expected to close in the fourth quarter of this year and is subject to customary closing conditions and regulatory clearances.

The acquisition is expected to enhance IBM’s product engineering expertise and provide end-to-end digital transformation services for clients. Upon close, Dialexa will join IBM Consulting, strengthening IBM’s digital product engineering services presence in the Americas.

Founded in 2010 and led by CEO Scott Harper, Dialexa delivers a suite of digital product engineering services, enabling organizations to create new products to drive business outcomes. The company has deep experience delivering end-to-end digital product engineering services consisting of strategy, design, build, launch, and optimization services across cloud platforms including AWS and Microsoft Azure. Its team of 300 product managers, designers, full-stack engineers and data scientists, based in Dallas and Chicago, advise and create custom, commercial-grade digital products for clients such as Deere & Company, Pizza Hut US, and Toyota Motor North America.

FinSMEs

26/09/2022

Mon, 26 Sep 2022 15:12:00 -0500 FinSMEs en-US text/html https://www.finsmes.com/2022/09/ibm-acquires-dialexa.html
Killexams : High density power optimization kit full ibm 65lpe svt IP Listing No result found, try new keyword!Foundry sponsored - Two Port Register File compiler - TSMC 55 nm uLP - Memory optimized for high density and low power - Dual Voltage - compiler range up to 64 kbits Foundry sponsored - Dual Port SRAM ... Sun, 04 Sep 2022 12:00:00 -0500 en text/html https://www.design-reuse.com/sip/?q=high+density+power+optimization+kit+full+ibm+65lpe+svt Killexams : Aktana Welcomes New Medical Affairs Lead from IBM Watson Health (Now Merative)

The MarketWatch News Department was not involved in the creation of this content.

SAN FRANCISCO, (BUSINESS WIRE) -- Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes Deepak Patil as its new senior director of medical strategy. Patil comes to Aktana after leadership roles at IBM Watson Health, IQVIA, and Sun Pharma Industries (Mumbai, India), where he managed medical affairs in conjunction with six key product launches and developed lasting relationships with key opinion leaders in targeted therapeutic areas. At Aktana, Patil will lead the company’s medical affairs program, initially helping to build modern, data-driven solutions for medical science liaisons (MSLs), but over time, also expand to other areas within medical affairs.

Medical Affairs is the “third strategic pillar of the pharmaceutical organization alongside R&D and commercial, as science and data merge,” according to a McKinsey report. Business models are starting to evolve both around and beyond the “product” to encompass the wider therapeutic context, while organizations seek to explain and contextualize the ever more complex medical science to a diverse range of stakeholders (physicians, patients, payers). In outreach efforts, MSLs and commercial teams can unintentionally overlap, causing major compliance issues and frustrating doctors. Aktana’s intelligence solutions will not only help medical affairs Excellerate key opinion leader relationships but also better orchestrate outreach to the physician community in compliance with regional engagement regulations.

“Deepak brings a unique blend of medical experience – he received his medical degree in India – plus data science and operational expertise from IQVIA and IBM,” said Clay Hausmann, chief revenue officer at Aktana. “As we prioritize new, AI-driven solutions for medical affairs teams, Deepak will help expertly shape our new offerings while building a powerhouse team focused on this increasingly important area of life sciences.”

Aktana has also announced a strategic partnership with Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs. Envision and Aktana will combine their offerings to help MSLs address HCP demands for personalized scientific content and coordinated omnichannel engagement.

“Aktana is committed to enabling the medical affairs organization in a new era, and I’m excited to serve in a leadership role as part of this endeavor,” said Deepak Patil. “The real-world data is there. With the right technology, we have the power to Excellerate the generation and dissemination of scientific insights to physicians, leading to better treatment decisions and outcomes for their patients.”

With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine, which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements that will deliver the highest ROI.

About Aktana

Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220927005313/en/

SOURCE: Aktana

Lisa Barbadora
lbarbadora@barbadoraink.com
(610) 420-3413

COMTEX_415381600/2456/2022-09-27T07:33:29

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

The MarketWatch News Department was not involved in the creation of this content.

Mon, 26 Sep 2022 23:33:00 -0500 en-US text/html https://www.marketwatch.com/press-release/aktana-welcomes-new-medical-affairs-lead-from-ibm-watson-health-now-merative-2022-09-27
00M-243 exam dump and training guide direct download
Training Exams List